Thus, patients with KRAS- or NRAS-mutant tumours should be treated with a chemotherapy doublet (FOLFOX or FOLFIRI) or triplet (FOLFOXIRI) in combination with the anti-angiogenic antibody bevacizumab targeting the vascular endothelial growth factor A (VEGFA) in first line. This evidence concerns the gene VEGFA and neoplasm.